AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Notably, data showed a switch from the reference product to the biosimilar at week 12 had no impact on treatment outcomes. “We are proud to achieve the approval of the first biosimilar to ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar ...

Bach to Rock, America's modern music school for students of all ages, is excited to announce the launch of their mobile app version of "MyB2R," designed to make music education more accessible, ...

Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CTP43 or Reference Ustekinumab) in Patients with ...

Wezlana was also given interchangeable status by the FDA, allowing pharmacists in some states to switch patients from the reference product to the biosimilar without notifying prescribers.

Malcolm Qualie, pharmacy lead, specialised services at NHS England, says incentives to switch to biosimilars could help reduce the pressure on NHS budgets. Speaking in London at the Ethical ...